Results 161 to 170 of about 55,201 (251)

The Evolving Role of Ivabradine for Focal Atrial Tachycardia: A Systematic Review

open access: yesJournal of Arrhythmia, Volume 42, Issue 2, April 2026.
Overview of the evolving role of ivabradine in focal atrial tachycardia (FAT), highlighting its HCN‐mediated mechanism, features of ivabradine‐sensitive FAT, hypothesized predictors of response, special populations requiring special considerations, and potential adverse effects.
Haikal Balweel   +5 more
wiley   +1 more source

The Incremental Prognostic Value of Hyperemic Coronary Flow Velocity in Patients with Angina and Nonobstructive Coronary Artery Disease

open access: yesMedComm, Volume 7, Issue 4, April 2026.
Patients were first split by CFVR (≥ 2.5 vs. < 2.5). Among those with CFVR < 2.5, peak hyperemic CFV (hCFV) further defined Group B (> 0.44 m/s) and Group C (≤ 0.44 m/s). This hCFV‐guided split identified the ceiling of risk: Group C showed the highest MACE incidence, while Group B had substantially lower risk, consistent with pseudo‐low CFVR driven by
Quande Liu   +10 more
wiley   +1 more source

Green Hydrogels Based on Spirulina Pl. Polysaccharides and Carboxymethyl Cellulose for Atenolol Pharmaceutical Compound Removal from Wastewaters

open access: yesChemistrySelect, Volume 11, Issue 16, 27 April 2026.
The synthesis and characterization of green, environmentally and economically sustainable hydrogel adsorbents is reported, while its efficiency towards the removal of atenolol is evaluated by batch adsorption experiments. Thermally‐triggered esterification reaction between citric acid and the biopolymers led to development of highly efficient, water ...
Pavlos Efthymiopoulos   +5 more
wiley   +1 more source

Audiological Profile in Patients of Chronic Stable Angina with Hearing Loss. [PDF]

open access: yesIndian J Otolaryngol Head Neck Surg
Dwivedi P   +6 more
europepmc   +1 more source

Safety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2‐Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open‐Label, Single‐Arm, Phase IV Study

open access: yesAsia-Pacific Journal of Clinical Oncology, Volume 22, Issue 2, Page 240-250, April 2026.
A phase IV, single‐arm, open‐label, multicenter study assessing the safety and efficacy of trastuzumab emtansine in Indian patients for the treatment of human epidermal growth factor receptor 2 (HER2)‐positive unresectable locally advanced or metastatic breast cancer who received prior treatment with trastuzumab and a taxane.
Sudeep Gupta   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy